RecensMedical, Inc.

As of June 30, 2026, RecensMedical, Inc. carries a market capitalization of 175.99B, placing it among publicly traded companies globally. Its enterprise value stands at 168.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, RecensMedical, Inc. has 10.85M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 26.07, and the price-to-book ratio stands at 8.86.

These figures are as of June 30, 2026. The EV/Sales ratio of 25.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 168.30B versus a market cap of 175.99B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, RecensMedical, Inc. maintains a current ratio of 4.02, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.10, indicating elevated leverage, while an interest coverage ratio of -60.94 demonstrates limited ability to service its debt obligations.

These figures are as of the close on October 23, 2026.

Over the twelve months ended June 30, 2026, RecensMedical, Inc. generated 6.52B in revenue and converted that into -11.05B in net income, yielding earnings per share of -1,053.88. EBITDA reached -11.12B, while operating income came in at -11.74B.

As of June 30, 2026, RecensMedical, Inc. holds 13.67B in cash and equivalents against 5.98B in total debt, resulting in a net debt position of 1.48B. Total book value stands at 19.86B, with working capital of 18.84B providing operational flexibility.

RecensMedical, Inc. produced -11.27B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.24B in capital expenditures, free cash flow totaled -12.51B - equivalent to -1,193.47 per share.

Over the twelve months ended June 30, 2026, RecensMedical, Inc. posted a gross margin of 53.63, reflecting its pricing power and cost economics. The operating margin of -180.08 and net profit margin of -169.40 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.36: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -12.40, meaning RecensMedical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, RecensMedical, Inc. has an Altman Z-Score of 4.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.